Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Cells. 2021 Dec 30;11(1):113. doi: 10.3390/cells11010113.
Patient adherence to medications for common skin conditions has been extensively studied over the past two decades, and suboptimal adherence is a primary contributor to treatment failure. The impact of sub-par adherence in cutaneous T-cell lymphoma (CTCL) patients has been largely unexplored, and promoting adherence in this patient population may represent a promising area of consideration for improving treatment outcomes. We apply patient adherence strategies that have been studied in dermatology to CTCL and provide concrete examples of how these strategies can be used to improve adherence in the CTCL setting. Through the implementation of small changes in how we present and counsel about therapeutic options to our patients, we can maximize patient adherence, which has the potential to optimize therapy regimens and reduce treatment failure.
在过去的二十年中，人们广泛研究了常见皮肤疾病患者对药物的依从性，而不依从治疗是导致治疗失败的主要原因之一。皮肤 T 细胞淋巴瘤 (CTCL) 患者中不依从治疗的影响在很大程度上尚未得到探索，而提高这一患者群体的依从性可能是改善治疗结果的一个值得关注的领域。我们将已经在皮肤科中研究过的患者依从策略应用于 CTCL，并提供了具体示例，说明如何在 CTCL 环境中使用这些策略来提高依从性。通过改变我们向患者介绍和建议治疗方案的方式，我们可以最大限度地提高患者的依从性，这有可能优化治疗方案并减少治疗失败。
